TrialClinical rheumatology2022

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.

Laura C Coates et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.